Table 3 Clinical characteristics of candidates with IPF (n = 57) and non-IPF ILD (n = 57)
IPF (n = 57) | non-IPF ILD (n = 57) | p value | |
|---|---|---|---|
Age, median (IQR) | 50 (44–56) | 47 (37–52) | 0.039 |
Sex, male (%) | 45 (78.9) | 32 (56.1) | 0.016 |
Body mass index (kg/m2), median (IQR) | 22.6 (18.8–26.2) | 19.8 (16.4–24.5) | 0.053 |
Pre-transplant condition, n (%) | |||
History of malignancy | 3 (5.3) | 7 (12.3) | 0.321 |
Connective tissue disorders | 2 (3.5) | 33 (57.9) | < .001 |
Supplemental oxygen | 44 (77.2) | 48 (84.2) | 0.476 |
Pulmonary function, median (IQR) | |||
Predicted FVC | 49.0 (32.9–64.9) | 43.7 (29.9–56.8) | 0.314 |
6 min walk (m) | 273 (138–369) | 300 (203–370) | 0.449 |
Estimated RVP (mmHg) | 34 (23–47) | 35 (25–47) | 0.849 |
Laboratory values, median (IQR) | |||
Hemoglobin (g/dL) | 14.0 (12.6–15.1) | 13.5 (12.3–15.0) | 0.399 |
Albumin (g/dL) | 3.8 (3.5–4.1) | 3.9 (3.6–4.1) | 0.444 |
Creatinine (mg/dL) | 0.72 (0.61–0.83) | 0.90 (0.55–0.81) | 0.116 |
Outcomes, n (%) | 0.039 | ||
Transplanted | 13 (22.8) | 18 (31.6) | |
Dead | 35 (61.4) | 23 (40.4) | |
Waiting (on March 2021) | 9 (15.8) | 16 (28.1) | |
Wait time, median day (IQR) | |||
Time to transplant (n = 13, 18) | 738 (291–913) | 651 (464–850) | 0.977 |
Time to death (n = 35, 23) | 278 (98–512) | 396 (122–514) | 0.623 |
Time to events/censoring (n = 57, 57) | 378 (160–572) | 495 (226–646) | 0.267 |